BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fremeaux-Bacchi V. Treatment of atypical uraemic syndrome in the era of eculizumab. Clin Kidney J 2012;5:4-6. [PMID: 26069738 DOI: 10.1093/ckj/sfr177] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Cochat P, Harambat J, Leclerc A. Recurrent Disease in Pediatric Renal Transplantation. Curr Pediatr Rep 2013;1:60-7. [DOI: 10.1007/s40124-012-0004-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F, Salardi S, Tedeschi S, Belingheri M, Cugno M. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis. 2014;64:633-737. [PMID: 24656451 DOI: 10.1053/j.ajkd.2014.01.434] [Cited by in Crossref: 132] [Cited by in F6Publishing: 106] [Article Influence: 16.5] [Reference Citation Analysis]
3 Koutroutsos K, Jardine J, Ross L, Papageorghiou A, Stasi R, Banerjee D. A curious case of haemolysis, seizure and acute renal failure associated with pregnancy. J Nephrol 2014;27:345-8. [PMID: 24482089 DOI: 10.1007/s40620-013-0007-2] [Reference Citation Analysis]
4 Rodriguez E, Barrios C, Soler MJ. Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome? Clin Kidney J 2017;10:320-2. [PMID: 28616209 DOI: 10.1093/ckj/sfx024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
5 Ferreira E, Oliveira N, Marques M, Francisco L, Santos A, Carreira A, Campos M. Eculizumab for the treatment of an atypical hemolytic uremic syndrome with mutations in complement factor I and C3. Nefrologia 2016;36:72-5. [PMID: 26541438 DOI: 10.1016/j.nefro.2015.07.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
6 Smith-Jackson K, Yang Y, Denton H, Pappworth IY, Cooke K, Barlow PN, Atkinson JP, Liszewski MK, Pickering MC, Kavanagh D, Cook HT, Marchbank KJ. Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice. J Clin Invest 2019;129:1061-75. [PMID: 30714990 DOI: 10.1172/JCI99296] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
7 Besbas N, Gulhan B, Karpman D, Topaloglu R, Duzova A, Korkmaz E, Ozaltin F. Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab. Pediatr Nephrol 2013;28:155-8. [PMID: 22956028 DOI: 10.1007/s00467-012-2296-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]